MAPK3 and melanoma: Despite these limitations, this study can clearly indicate that targeting ERK1/2 pathway induces rapid adaptation of initially drug-responsive melanomas through phospho-regulation of multi pathways, and inhibition of BMK1 has therapeutic potential for the treatment of melanoma.